T helper type 1 cells (Th1) become anergic when stimulated through the antigen receptor in the absence of costimulation. They do not produce IL-2 or proliferate in response to subsequent stimulation. Previous studies have indicated that anergic T cells are defective in the trnsactivational activity of the transcription factor, AP-1, which is required for optimal IL-2 transcription. Using two murine Th1 cell clones, we demonstrate that anergic Th1 cells have defects in both jun NH2-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activities. These kinases have been shown to be important for the upregulation of AP-1 activity. Furthermore, our data show that ERK and JNK activities are restored when anergy is induced in the presence of the protein synthesis inhibitor cycloheximide, or when anergic T cells are allowed to proliferate in response to exogenous IL-2. These treatments have previously been shown to prevent or reverse the anergic state. Our results suggest that defects in both JNK and ERK may result in the decreased AP-1 activity and the reduced IL-2 transcription observed in anergic T cells.
Skip Nav Destination
Article navigation
1 May 1996
Article|
May 01 1996
Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways.
D R DeSilva,
D R DeSilva
Dupont Merck Pharmaceutical Company, Inflammatory Diseases Research, Wilmington, Delaware 19880-0400, USA.
Search for other works by this author on:
W S Feeser,
W S Feeser
Dupont Merck Pharmaceutical Company, Inflammatory Diseases Research, Wilmington, Delaware 19880-0400, USA.
Search for other works by this author on:
E J Tancula,
E J Tancula
Dupont Merck Pharmaceutical Company, Inflammatory Diseases Research, Wilmington, Delaware 19880-0400, USA.
Search for other works by this author on:
P A Scherle
P A Scherle
Dupont Merck Pharmaceutical Company, Inflammatory Diseases Research, Wilmington, Delaware 19880-0400, USA.
Search for other works by this author on:
D R DeSilva
Dupont Merck Pharmaceutical Company, Inflammatory Diseases Research, Wilmington, Delaware 19880-0400, USA.
W S Feeser
Dupont Merck Pharmaceutical Company, Inflammatory Diseases Research, Wilmington, Delaware 19880-0400, USA.
E J Tancula
Dupont Merck Pharmaceutical Company, Inflammatory Diseases Research, Wilmington, Delaware 19880-0400, USA.
P A Scherle
Dupont Merck Pharmaceutical Company, Inflammatory Diseases Research, Wilmington, Delaware 19880-0400, USA.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1996) 183 (5): 2017–2023.
Citation
D R DeSilva, W S Feeser, E J Tancula, P A Scherle; Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways.. J Exp Med 1 May 1996; 183 (5): 2017–2023. doi: https://doi.org/10.1084/jem.183.5.2017
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement